Table 1.
Baseline characteristics in people with AChR-Ab+ gMG who were included in the ADAPT and CHAMPION studies
| Characteristic | ADAPTa | CHAMPION | ||||
|---|---|---|---|---|---|---|
| Total (n = 111) |
Efgartigimod (n = 55) |
Placebo (n = 56) |
Total (n = 175) |
Ravulizumab (n = 86) |
Placebo (n = 89) |
|
| Mean (SD) | ||||||
| Age at enrolment, years | 47.3 (15.8) | 45.0 (15.5) | 49.7 (15.7) | 55.6 (15.1) | 58 (13.8) | 53.3 (16.1) |
| Age at diagnosis, years | 37.6 (18.0) | 35.2 (17.8) | 39.9 (18.1) | 46.1 (18.9) | 48.6 (18.5) | 43.7 (19) |
| Years from diagnosis to randomization | 9.8 (8.4) | 9.8 (8.6) | 9.8 (8.3) | 9.9 (9.3) | 9.8 (9.7) | 10 (8.9) |
| Baseline clinical disease activity | ||||||
| MG-ADL score | 9.2 (2.1) | 9.5 (2.2) | 8.8 (2.0) | 9.0 (2.5) | 9.1 (2.6) | 8.9 (2.3) |
| QMG score | 15.8 (4.8) | 16.3 (5.2) | 15.3 (4.3) | 14.7 (5.2) | 14.8 (5.2) | 14.5 (5.3) |
| MG-QoL15r score | 16.8 (5.5) | 16.4 (5.8) | 17.2 (5.2) | – | – | – |
| Count (%) | ||||||
| Woman | 75 (67.6) | 40 (72.7) | 35 (62.5) | 89 (50.9) | 44 (51.2) | 45 (50.6) |
| Race/ethnicity | ||||||
| Asian | 10 (9.0) | 6 (10.9) | 4 (7.1) | 31 (17.7) | 15 (17.4) | 16 (18.0) |
| African/American | 2 (1.8) | 0 (0.00) | 2 (3.6) | 6 (3.4) | 2 (2.3) | 4 (4.5) |
| White | 95 (85.6) | 46 (83.6) | 49 (87.5) | 128 (73.1) | 67 (77.9) | 61 (68.5) |
| Other | 3 (2.7) | 3 (5.4) | 0 (0.00) | 3 (1.7) | 0 (0.0) | 3 (3.4) |
| Not reported | 1 (0.9) | 0 (0.00) | 1 (1.8) | 7 (4.0) | 2 (2.3) | 5 (5.6) |
| Current/previous treatments | ||||||
| Prior thymectomy | 62 (55.9) | 36 (65.5) | 26 (46.4) | – | – | – |
| Glucocorticoids | 84 (75.7) | 39 (70.9) | 45 (80.4) | 121 (69) | 56 (65) | 65 (73) |
| Other NSID | 66 (59.5) | 33 (60.0) | 33 (58.9) | 119 (68) | 56 (65) | 63 (71) |
| MGFA clinical class | ||||||
| Class I | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Class II | 43 (38.7) | 20 (36.3) | 23 (41.1) | 78 (44.6) | 39 (45.3) | 39 (43.8) |
| Class III | 63 (56.8) | 33 (60.0) | 30 (53.6) | 86 (49.1) | 41 (47.7) | 45 (50.6) |
| Class IV | 5 (4.5) | 2 (3.6) | 3 (5.4) | 11 (6.3) | 6 (7.0) | 5 (5.6) |
AChR-Ab+ acetylcholine receptor auto-antibody-positive, gMG generalized Myasthenia Gravis, MGFA Myasthenia Gravis Foundation of America, NSID non-steroidal immunosuppressive drug, SD standard deviation, – indicates that data were not reported
aDemographics are shown for the 111 patients in the ADAPT study who were included in the analyses presented in this manuscript